Regeneron Turned Away in Challenge to Novartis Syringe Patent

Regeneron can’t count on the Patent Trial and Appeal Board to invalidate Novartis patent 9,220,631 for a pre-filled syringe used in the treatment of retinal diseases, the board ruled late Friday.

• The board declined to institute a review of the Novartis patent, saying it would be duplicative of advanced proceedings at the U.S. International Trade Commission
• The ITC, known for its relative speed in handling patent disputes, is scheduled to hear the case in April and complete the investigation by November
• Novartis is seekingto block imports of Regeneron’s Eylea PFS, saying the drug’s active ingredient can still be sold ...